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Abstract
Paediatric practitioners interact with industry representatives for many purposes but most often to receive information on
new and existing products. While practitioners believe they are immune to the marketing influences exerted by these representatives, research has demonstrated otherwise. The literature suggests that the public is aware of such influences and that
most people feel industry influence on practitioners is inappropriate. National guidelines go some way toward regulating
practitioner–industry interactions, although they are not always clear or sufficient. The present practice point explores the
context for these relationships, raises some ethical issues specific to paediatric practitioners and provides recommendations
for maintaining professional integrity in the patient–physician relationship. Paediatric practitioners have a professional duty
to ensure that their own interactions with industry are conducted with the best interests of the patient front and centre.
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BACKGROUND
Paediatric practitioners (practitioners) interact regularly with ‘industry’, which
for present purposes includes representatives from commercial organizations, the pharmaceutical industry, medical device manufacturers, nutritional
and health care product developers, as well as service suppliers. Practitioners
depend on industry to produce and distribute the products and services essential to medical practice. One national survey conducted in the United States
found that the vast majority of physicians (94%) reported having relationships
with industry, with physicians in private or group practices meeting with industry sales representatives more frequently than physicians in hospitals and clinics (1). In these interactions, physicians believe themselves to be immune to
industry influence, although colleagues are not always credited with the same
immunity (2).
The industry spends billions of dollars annually employing representatives to
meet with physicians, with the goal of increasing profits (3). The public is aware
of such marketing efforts, with 59% of participants from one study responding
that industry influences doctors’ prescribing practices, and 54% rating ‘gifts’
irrelevant to medical practice as either inappropriate or extremely inappropriate
(4,5) The present practice point outlines some important potential concerns
for practitioners in this relationship, along with ethical considerations, existing
guidelines and recommendations for how to negotiate at times difficult interactions with industry. Considerations around industry-sponsored research, while
very important, are beyond the scope of this practice point.
The paediatric practitioner’s role is to provide the best care for infants, children and adolescents, using current evidence-based knowledge, while making a
reasonable living. Industry’s role is to provide safe and effective health care products while returning a profit to company shareholders (6). Both practitioners and

patients depend on industry to develop new products and bring them to market,
and busy practitioners often rely on industry representatives for product information. However, practitioners must remain aware of potential biases in the information presented by industry representatives and critically appraise the current
literature as part of routine practice, always recognizing that an industry representative’s goal is to portray their product favourably (7). Occasionally, product information is conveyed over a meal or accompanied by a trinket with the company
logo. While this may be how business is transacted in other sectors of the economy, it may not be appropriate in the medical setting. Practitioners are responsible
for providing evidence-based medical care that has not been biased by marketing.
In any marketing relationship, giving even a token ‘gift’ can create a sense of
obligation that may prove ‘influential’ (8). Patients might well question whether
a practitioner has the patient’s best interests at heart when the practitioner writes
a prescription for a medication using a pen bearing the manufacturer's logo. It
could be even more problematic for patients to learn that this company covered
expenses for a medical meeting to inform practitioners about their latest product. The practitioner’s first duty is to their patients, while industry’s duty is to
their shareholders. It is important to bear this distinction in mind when considering ethical ramifications of the practitioner–industry relationship.

ETHICAL CONSIDERATIONS
Beneficence
The practitioner, as fiduciary, has some degree of power to exercise on behalf
of each patient (or beneficiary), and a duty to act in their best interests.
Practitioners must continually ensure that their self-interest is not a factor
in relationships with patients and that the vulnerability of patients is never
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exploited (9). With this privileged relationship comes an ethical responsibility
to conduct a stringent arm’s–length relationship with industry.

Professionalism

Non-maleficence
It is all too easy for practitioners to find themselves in a conflict of interest
(COI) or to experience competing interests. These interests may result in an
actual COI, a perceived COI or a potential COI, defined as: ‘a situation in which
financial or other personal considerations have the potential to compromise or
bias professional judgment and objectivity’ (12). Relevant commercial ties
may be difficult to define clearly. Income received personally or paid to one’s
institution by a company whose product is being prescribed is a clear example. Another example is prescribing a product from a company in which you
are a shareholder. A relevant COI may result in practitioners considering their
own interests ahead of their patients’ and is not always as clearly defined as the
examples given here. As noted, small incentives can create expectations and
reciprocal impulses that are never made explicit. A perceived COI can lead to
loss of trust by patients, parents or other health care professionals. Harming the
patient–practitioner relationship is too great a risk: any real or potential COI
must be disclosed and resolved in the best interest of patients. Transparency is
the minimum standard in most developed countries (6,13).
The industry provides ‘free samples’ to help sell a product. This particular
marketing technique is employed because it establishes a ‘status quo bias’, where
physicians and patients do not wish to change medications if they are working
(14). Sometimes families cannot afford a specific treatment, but if the free sample is the standard of care and a child would otherwise not receive treatment,
then sample medications may be appropriate if provided for the entire course
of treatment.

REGULATIONS
Guidelines have been developed by various governing bodies to navigate the
practitioner–industry relationship (15–18), and it is important that practitioners familiarize themselves with both local and national policies.
The Canadian Medical Association (CMA) guideline identifies the physician’s obligation to disclose relevant ties to industry and the need to resolve
any COI in favour of patients. The guideline specifically states: “Practising physicians should not accept personal gifts of any significant monetary or other
value from industry” (15). The CMA guideline has been endorsed by the Royal
College of Physicians and Surgeons of Canada (RCPSC) (16), the Canadian
Paediatric Society (18), and many local health care institutions. The CMA regulations may not go far enough because, as has been demonstrated, even small
gifts can foster a sense of obligation on the part of practitioners (2).

In keeping with the CMA guideline, RCPSC policy limits continuing medical
education (CME) sponsorship to “… modest meals or social events that are held as
part of a conference or meeting” and to funding faculty only for “reasonable honoraria and reimbursement for travel, lodging and meal expenses” (15). They emphasize that “Physicians must be vigilant in discerning the difference between education
and marketing” (16). To help deal with these concerns, accrediting bodies in most
industrialized countries have recommended an educational approach (19). In one
review of 10 studies, educational interventions were found to inform the attitudes
of residents, medical students and faculty toward industry (19). Another study confirmed these findings but identified that, despite familiarity with their Institution's
guidelines limiting interactions with industry, >20% of physicians rated accepting
dinner at a modest restaurant with no educational component as appropriate, while
nearly 10% rated the acceptance of an industry-funded vacation as appropriate (20).
The Association of American Medical Colleges has proposed stringent
guidelines to govern the interactions of physicians working in academic institutions vis à vis industry (17). Developing a set of comparable guidelines would
be beneficial for regulating these interactions in private practice as well.

RECOMMENDATIONS
The role of the paediatric practitioner is to act in the best interest of patients.
With regard to relationships with industry:
• Remember that industry is, first and foremost, in the business of selling
products and services.
• 
Fully evaluate information provided by industry for scientific merit.
Evaluation means exercising due diligence in investigating the risks and
benefits of new treatments and keeping abreast of the evidence-based literature concerning available treatment options.
• Fully disclose any relevant commercial ties with industry to patients in relation to prescribing practice.
• Do not accept gifts, inducements or even small tokens (e.g., pens, mugs)
which do not benefit patients.
• Do not accept or offer free samples, with the possible exception of situations
of social or financial need, such as when a child would not receive therapy
otherwise. For those cases, the samples must constitute appropriate therapy
and cover the duration of treatment.
• Fully disclose any relevant commercial ties with industry to committees
for whom this relationship may constitute a real, potential or perceived
conflict of interest.
• Organizers of continuing medical education may apply to industry for
unrestricted educational grants for educational activities that contribute to
the improvement of patient care. Support may include reasonable speaker
expenses and modest meals for course participants if meals are incidental to
the educational content of the meeting.
• Industry should not be involved in choosing speakers or content for continuing medical education presentations.
• Educational curriculum should be provided by training programs and
medical institutions on the ethics of interacting with industry and potential
impact on treatment bias, scientific objectivity and conflict of interest.

CONCLUSION
The role of the practitioner is to act in the best interest of the patient. In addition to ensuring due diligence in investigating the risks and benefits of available treatments and evaluating the evidence-based literature, the importance of
maintaining the integrity of the practitioner–patient relationship is paramount.
There is a need for complete transparency with respect to industry inducements
and for educational programs to build a better understanding of the relationship between practitioners and industry. In the final analysis, our fiduciary
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Personal integrity is essential to self-respect and professional reputation. By
and large, physicians do not feel they are personally influenced by industry (2).
However, whether or not a physician’s relationship with industry has influenced
prescribing practice is not the key question. The fact that this relationship is
capable of influencing medical practice is enough to warrant close scrutiny (8).
The primary motivation for industry gift-giving is to create an expectation of
reciprocity. Such gifts can compromise objectivity, professional behaviour and
the respect of patients, parents or colleagues. Gifts or other inducements that
do not benefit patients are intended to influence behaviour and should never be
accepted (10). Even token gifts such as pens, mugs or pads of paper, where the
primary purpose is to display the company logo, may adversely impact the trust
of patients and their families (11).
Practitioners are mentors and role models for students, trainees and junior
colleagues, some of whom are easily influenced. It is in everyone’s best interest
to ensure that practitioner relationships with industry are always transparent
and ethically justifiable.
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relationship with patients and the trust that is essential to the patient–practitioner relationship are too important to jeopardize.
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